Liver metastases in thyroid cancer: epidemiology, risk stratification and survival outcomes in the immunotherapy era.

Purpose: Liver metastases in thyroid cancer are rare but fatal, with poorly defined risk profiles and survival outcomes. This study aimed to characterize epidemiology, risk factors and outcomes of this disease using a population-based approach, further explore the potential impact of the immunotherapy era on the prognosis of these patients.

Methods: Data on 116,801 thyroid cancer cases from SEER program (2010-2021) were analyzed.

Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib.

Background: Although it remained fully unclear about the optimal regimen for Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistant non-small cell lung cancer (NSCLC) patients with Mesenchymal-Epithelial Transition factor (MET) amplification, the dual inhibition of EGFR inhibitor with MET inhibitor were attempted in clinical practice. There is very limited literature on the subsequent treatment when patients develop the resistance to this combination regimen.

Case Summary: The patient, a 49-year-old female, initially presented with EGFR exon 21 L858R metastatic lung adenocarcinoma, treated successfully with first-line afatinib on September 2022 with a progression-free survival (PFS) of 8.

The Association Between Tumor Burden and the Efficacy of Immunotherapy Among Patients With Non-small Cell Lung Cancer.

Background: This cohort study aimed to evaluate the impact of tumor burden (TB) on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC).

Materials And Methods: Data from the POPLAR and OAK trials were extracted as the training and validation cohorts, respectively. TB was defined as the sum of the longest dimensions (blSLD) of measurable target lesions as per RECIST v1.

[The Efficacy of Rh Phenotype Matched Blood Transfusion].

Objective: To analyze and evaluate the efficacy of Rh phenotype matched blood transfusion.

Methods: The increasing of hemoglobin (Hb) and hemolysis tests in the patients treated by Rh matched red blood cells or not, as well as the first time unmatched transfusions and the unmatched transfusions happened again after a period (≥10 d) were retrospectively analyzed.

Results: A total of 674 times transfusions in 120 patients were evaluated.